Brief: Sernova Receives Authorization To Enroll Second Patient Group For Type 1 Diabetes Trial
03/11/2022 11:58
Nov 3 (Reuters) - Sernova Corp SVA.TO :
* SERNOVA RECEIVES AUTHORIZATION TO ENROLL SECOND PATIENT
COHORT
OF PHASE 1/2 TRIAL WITH CELL POUCH SYSTEM™ FOR TYPE 1 DIABETES
Source text for Eikon: ID:nGNX1vrS4h
Further company coverage: SVA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sernova Biotherapeutics
See all newsBrief: Seraxis And Sernova Announce Appointment Of Former FDA Medical Officer Dr. Patricia Beaston As Chief Medical Officer Of Seraxis And Post Merger Betanova Biotherapeutics
Brief: Sernova Appoints Jonathan Rigby As Interim Chair
Brief: Sernova Biotherapeutics Provides Positive Interim Data From Ongoing Phase 1/2 Clinical Trial Of Cell Pouch Bio-Hybrid Organ In Patients Living With Type 1 Diabetes
Brief: Sernova Biotherapeutics Secures $4 Million Loan To Further Advance Its Clinical Development Plans
Brief: Sernova Biotherapeutics Inc Study Is On Track To Meet Key Clinical Trial Endpoints